Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ARVN 
Arvinas Inc (ARVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: ARVN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $18.44
1 Year Target Price $18.44
| 9 | Strong Buy |
| 4 | Buy |
| 8 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.65% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 568.25M USD | Price to earnings Ratio - | 1Y Target Price 18.44 |
Price to earnings Ratio - | 1Y Target Price 18.44 | ||
Volume (30-day avg) 21 | Beta 2.39 | 52 Weeks Range 5.90 - 29.61 | Updated Date 09/14/2025 |
52 Weeks Range 5.90 - 29.61 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -19.47% | Operating Margin (TTM) -314.73% |
Management Effectiveness
Return on Assets (TTM) -6.71% | Return on Equity (TTM) -12.01% |
Valuation
Trailing PE - | Forward PE 17.7 | Enterprise Value -283047815 | Price to Sales(TTM) 1.52 |
Enterprise Value -283047815 | Price to Sales(TTM) 1.52 | ||
Enterprise Value to Revenue 5.69 | Enterprise Value to EBITDA -1.62 | Shares Outstanding 73417600 | Shares Floating 62205994 |
Shares Outstanding 73417600 | Shares Floating 62205994 | ||
Percent Insiders 6.85 | Percent Institutions 94.18 |
Upturn AI SWOT
Arvinas Inc
Company Overview
History and Background
Arvinas Inc. was founded in 2013 by Dr. Craig Crews at Yale University. It pioneered the development of PROTAC (PROteolysis TArgeting Chimera) technology, which harnesses the body's natural protein degradation system to destroy disease-causing proteins. The company has focused on developing novel therapies for cancer and other diseases.
Core Business Areas
- Protein Degradation Therapeutics: Arvinas's primary focus is on developing PROTAC-based therapies for oncology and other diseases. They are leading the advancement of targeted protein degradation as a new therapeutic modality.
- Clinical Development: Arvinas is advancing multiple programs into clinical development, testing the efficacy and safety of their PROTAC degraders in various patient populations.
Leadership and Structure
Arvinas is led by CEO John Houston. The organizational structure includes research, development, clinical, and commercial functions, all focused on the discovery and development of PROTAC-based therapies.
Top Products and Market Share
Key Offerings
- Bavdegalutamide (ARV-110): An oral PROTAC degrader targeting the androgen receptor (AR) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This has shown clinical activity in heavily pretreated mCRPC patients. Competitors include androgen receptor signaling inhibitors (ARSI) such as enzalutamide (Xtandi) and abiraterone (Zytiga).
- Vepdegestrant (ARV-471): An oral PROTAC degrader targeting the estrogen receptor (ER) for the treatment of ER-positive/HER2-negative breast cancer. This is being developed to overcome resistance to existing endocrine therapies. Competitors include selective estrogen receptor degraders (SERDs) such as fulvestrant and selective estrogen receptor modulators (SERMs) like tamoxifen and aromatase inhibitors
Market Dynamics
Industry Overview
The pharmaceutical industry is experiencing rapid innovation in targeted therapies and protein degradation technologies. There's an increasing demand for new approaches to treat diseases resistant to existing drugs.
Positioning
Arvinas is a leader in the protein degradation field, leveraging its PROTAC technology to create novel therapeutic candidates. Its competitive advantage lies in its pioneering technology and clinical pipeline.
Total Addressable Market (TAM)
The TAM for protein degradation therapeutics is estimated to be in the billions of dollars, given its potential application across multiple disease areas. Arvinas is positioned to capture a significant portion of this TAM with its lead programs in oncology.
Upturn SWOT Analysis
Strengths
- Pioneering PROTAC technology
- Strong intellectual property portfolio
- Promising clinical trial results
- Experienced management team
- Strategic partnerships with large pharmaceutical companies
Weaknesses
- Early stage of development
- Clinical trial risks and regulatory hurdles
- Reliance on partnerships for funding
- Manufacturing complexities of PROTAC molecules
- Limited commercialization experience
Opportunities
- Expansion of PROTAC technology to new disease areas
- Partnerships for combination therapies
- Advancements in PROTAC drug delivery
- Potential for breakthrough therapy designations
- Acquisition or licensing deals with large pharmaceutical companies
Threats
- Competition from other protein degradation technologies
- Clinical trial failures
- Regulatory delays or rejection
- Patent challenges
- Economic downturn affecting pharmaceutical investment
Competitors and Market Share
Key Competitors
- SNY
- MRK
- PFE
Competitive Landscape
Arvinas has a unique approach with its PROTAC technology but faces competition from companies developing traditional small molecule inhibitors and other targeted therapies. Its success hinges on demonstrating superior efficacy and safety in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Arvinas's growth has been driven by the advancement of its clinical programs and strategic partnerships.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization efforts. Analyst estimates vary based on these factors.
Recent Initiatives: Recent initiatives include expanding clinical trials for ARV-110 and ARV-471, forming new partnerships, and advancing preclinical programs.
Summary
Arvinas is a biotech leader in targeted protein degradation, pioneering PROTAC technology. While still early-stage with clinical trial risks, promising data and strategic partnerships drive growth. Competition and regulatory hurdles remain key considerations, but the company's innovative approach positions it for future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Arvinas Inc. Investor Relations
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arvinas Inc
Exchange NASDAQ | Headquaters New Haven, CT, United States | ||
IPO Launch date 2018-09-27 | Chairperson, CEO & President Dr. John G. Houston Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 430 | Website https://www.arvinas.com |
Full time employees 430 | Website https://www.arvinas.com | ||
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.